key: cord-0974143-i6jfylol
authors: Sudlow, C.; Diggle, P.; Warlow, O.; Seymour, D.; Gordon, B.; Walker, R.; Warlow, C.
title: Testing for coronavirus (SARS-CoV-2) infection in populations with low infection prevalence: the largely ignored problem of false positives and the value of repeat testing
date: 2020-08-22
journal: nan
DOI: 10.1101/2020.08.19.20178137
sha: 4312a29b988db89b981987fe88382b2ff22b4596
doc_id: 974143
cord_uid: i6jfylol

Background: Calls are increasing for widespread SARS-CoV-2 infection testing of people from populations with a very low prevalence of infection. We quantified the impact of less than perfect diagnostic test accuracy on populations, and on individuals, in low prevalence settings, focusing on false positives and the role of confirmatory testing. Methods: We developed a simple, interactive tool to assess the impact of different combinations of test sensitivity, specificity and infection prevalence in a notional population of 100,000. We derived numbers of true positives, true negatives, false positives and false negatives, positive predictive value (PPV, the percentage of test positives that are true positives) and overall test accuracy for three testing strategies: (1) single test for all; (2) add repeat testing in test positives; (3) add further repeat testing in those with discrepant results. We also assessed the impact on test results for individuals having one, two or three tests under these three strategies. Results: With sensitivity of 80%, infection prevalence of 1 in 2,000, and specificity 99.9% on all tests, PPV in the tested population of 100,000 will be only 29% with one test, increasing to >99.5% (100% when rounded to the nearest %) with repeat testing in strategies 2 or 3. More realistically, if specificity is 95% for the first and 99.9% for subsequent tests, single test PPV will be only 1%, increasing to 86% with repeat testing in strategy 2, or 79% with strategy 3 (albeit with 6 fewer false negatives than strategy 2). In the whole population, or in particular individuals, PPV increases as infection becomes more common in the population but falls to unacceptably low levels with lower test specificity. Conclusion: To avoid multiple unnecessary restrictions on whole populations, and in particular individuals, from widespread population testing for SARS-CoV-2, the crucial roles of extremely high test specificity and of confirmatory testing must be fully appreciated and incorporated into policy decisions.

However accurately some diagnostic tests may perform in well-controlled laboratory conditions, no test is 100% accurate in real-world clinical settings. Most science and media coverage and debate about the accuracy of molecular testing for SARS-CoV-2 coronavirus infection has focused on the problem of 'false negatives', where people with the virus have a negative test result when they should test positive. A perfect test would be 100% sensitivei.e., all cases infected with the virus should test positive. There are several reasons for less than 100% sensitivity with molecular tests for current SARS-CoV-2 infection (as distinct from antibody tests, aimed at detecting evidence of prior infection), including imperfect nasal and throat swabbing technique, insufficient virus present, laboratory error, and timing (i.e., after infection, the virus may take some time to appear in the nose and throat and then disappears at some point during the course of the infection).

One unfortunate consequence of false negatives is that people who really are infected with the virus may be reassured by a negative test (especially if they are asymptomatic or presymptomatic) and go on to infect others, perhaps by going back to work in a care home or factory where social distancing is challenging. However, the false negative problem is far less of an issue if someone is very likely to have SARS-CoV-2 coronavirus infection, for example if he or she is in a care home with many other residents testing positive, and has a cough, breathlessness, fever and hypoxia. The negative test would not put a doctor off diagnosing SARS-CoV-2 coronavirus infection ("if it looks like a duck and quacks it probably is a duck"), managing the patient appropriately, and maybe ordering another test. In other words, experienced clinicians will generally (and quite appropriately) ignore a negative test if on clinical grounds infection is highly likely.

By contrast, there has been much less discussion about the problem of 'false positives', which relate to what is referred to as the specificity of the test. A 100% specific test, the perfect test, would be negative in everyone tested who did not have the virus. Anything less than 100% specificity inevitably leads to some truly virus-free people testing positive: false positives.

Possible reasons for a false positive result include cross reactivity with another virus, sample contamination, and laboratory error.

Unfortunately, as the true frequency (or prevalence) of infection becomes less and less in any population, the problem of false positive tests becomes far more of an issue, even with a . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20178137 doi: medRxiv preprint highly specific test. The lower the prevalence, the higher will be the proportion of false positive results among all the positive results of even an almost perfectly specific test. This relationship is incredibly important for countries such as the UK (and many others across Europe and elsewhere), where the percentage of individuals in the community who are actively infected is currently very low (<0.1% in the UK in late July), 1 but where increasing numbers of prominent scientists and politicians are calling for widespread testing of asymptomatic people from these low prevalence populations. [2] [3] [4] [5] [6] We aimed to provide a simple, transparent tool to help policy makers, the scientific community, health professionals, journalists and the public understand the problem of incorrect test results, and to demonstrate how this problem may be addressed by conducting a second or even third test. In particular, we wished to highlight the issue of false positive results in low prevalence settings, and to draw attention to the possible unintended adverse consequences for populations and individuals if these are not fully understood.

We implemented a probabilistic calculation as an interactive tool within a Microsoft Excel spreadsheet workbook (https://www.hdruk.ac.uk/projects/false-positives/). The tool requires three input parameters: the prevalence of infection in the population from which the individuals being tested are drawn; test sensitivity; and test specificity. These parameters can be varied interactively so that the results of different scenarios can be examined. We present the results in three different formats:

to assess population level impact and inform population level policies, the numbers of people from a population of 100,000, all of whom are tested, who end up with true positive, true negative, false positive and false negative status after testing strategies with one, two or three rounds of testing (the 'model mass testing' worksheet);

(ii) to assess impact on and inform guidance for individuals, the interpretation of test is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20178137 doi: medRxiv preprint For all of these output formats, repeated tests are assumed to be conducted on the same day, as the tool is designed to address the issue of incorrect test results at a particular time point, rather than to deal with variation in the probability of detecting the virus at different times during the course of infection. The repeat testing strategy is designed to be appropriate for a low prevalence situation, where all people with a positive test in the first round have a second test (in an attempt to confirm positivity and so minimize false positives), and all people with a negative test in the second round have a third test (in an attempt to resolve the situation where tests from rounds one and two yield discrepant results).

The tool can be used to illustrate a wide range of scenarios for different potential values of infection prevalence, sensitivity and specificity. Here we use the tool's outputs to illustrate a few plausible scenarios that could arise when population prevalence of infection is low, as is currently the case in the UK.

Prevalence: Since mid-May, the Office for National Statistics has published the results of weekly coronavirus infection surveys, reporting that between 1 in 4000 and 1 in 1000 people within the community population in England were infected with SARS-CoV-2 during any one of the weeks from mid-May to early August. 1 For our initial illustrative scenario, we assume that about 1 in 2,000 people in the population (i.e., 0.05%) are infected. To illustrate what might happen with testing in a higher prevalence setting (e.g., a different country with higher prevalence of infection in the community, a town that has had a series of small outbreaks, or a large school where several pupils are thought to have been infected), we also consider scenarios where the prevalence is 20 times higher (i.e., 1% or 1 in 100). For graphical outputs, we consider prevalence values ranging from 0.05-10%.

Test specificity: Independent evaluations of molecular assays for SARS-CoV-2 infection performed in a single university hospital laboratory have found that around 95 to 100 % of samples with no virus present tested negative with the various molecular assays for SARS-CoV-2 infection. 7 For our initial illustrative scenario we assume that the best test specificity possible is 99.9% and show the highly optimistic results that would arise with a test specificity of 99.9% for all three rounds of testing. A specificity of 99.9% means that 0.1% (100 -99.9%) of all truly virus-free people tested will have a falsely positive test, i.e., one false positive result out of every 1000 virus-free people tested. We also show results for a more plausible specificity of 95% for the first round of tests and 99.9% for the smaller number of second and third round tests, assuming that these are conducted with highly optimized sample collection, sample transfer and laboratory analysis procedures. Finally, we show results arising when . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20178137 doi: medRxiv preprint specificity is 95% for all three rounds of testing. For graphical outputs, we consider specificities in the range 90-99.9%.

The same independent evaluation source reported that around 90 to 100 % of samples with the virus present tested positive, 7 although others have reported test sensitivity to be highly variable and often lower in clinical practice (from around 30 to 90%). 6 We show here the results for a sensitivity level of 80%, based on reports of test performance in clinical practice from the more promising end of the spectrum. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20178137 doi: medRxiv preprint

For six scenarios, based on six different combinations of parameters, Table 1 shows, for each testing strategy applied to our population of 100,000, the number of tests performed, the 

After testing all 100,000 people, the expected outcome is that:  this will leave 100 people who do not have infection but with a false positive test.

Hence 140 people will have a positive test, of whom 40 (29% of the positive tests) will be true positives and 100 (71%) will be false positives. On the other hand, 99,860 people will have a negative test, of whom 99,850 will be true negatives and only 10 will be false negatives (i.e., missed cases of infection).

Since such a large percentage of the 140 positive results of the first round of testing are false positives, a sensible strategy is to conduct a further test (immediately) on these 140 people.

In this illustrative scenario, test sensitivity and specificity remain the same, but now the prevalence of infection in the tested population is much higher, 40 in 140 (29%). After retesting these 140 people, the expected outcome is that:

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. Although the second round of testing reduced the proportion of those whose positive result was a false positive from 71% to 0%, there may be concerns about the increase in false negatives (missed cases of infection), which in this population of 100,000 people has almost doubled after the second round of testing from 10 to 18. This concern can be addressed -to some extent, at least -by conducting a further set of tests in the 108 people whose second test was negative (i.e. those with discrepant results from the first and second rounds). Of these 108 people, 8 are true cases, so the prevalence of infection for this round of testing is around 7%. After re-testing these 108 people, the expected outcome is that:

 at 80% sensitivity (given that we are rounding to the nearest whole number of people), 6 of the 8 true cases will now be detected as true positives, leaving 2 false negatives; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20178137 doi: medRxiv preprint

The remainder of Table 1 shows the results of this same reasoning process applied to the other scenarios. It also shows the additional number of tests required for rounds 2 and 3 of testing to enable strategies 2 and 3, as well as the PPV (i.e. the percentage of positive results that are true positives) and the overall accuracy (the percentage of all test results that are correct) for each strategy. All scenarios yield high overall accuracy, because at low prevalence most people are correctly identified as negative. This does not helpfully distinguish the pros and cons of different testing strategies. However, the results in Table 1 also show how the PPV increases at higher population infection prevalence. The critical importance of extremely high specificity in these low prevalence settings is also demonstrated: only when specificity is 99.9%, either across all rounds of testing or -more realistically -for the smaller numbers of round two and three tests, does the PPV reach around 80% or higher. Where all rounds of testing have specificities of 95% (which is also plausible in real-world settings), the PPV may be as low as 11% at best when prevalence is 1 in 2,000 (0.05%) or 72% at best when prevalence is 1 in 100 (1%). Finally, despite needing more tests, adding the third round of testing leads to no improvement and/or a slight reduction in the PPV. The advantage of strategy 3 is a small reduction in the number of false negatives (i.e. missed cases of infection), but at the cost of a more complex strategy, more tests, and more people with incorrect positive test status (false positives). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20178137 doi: medRxiv preprint

For the same scenarios, Table 2 11.4% at best) when population infection prevalence is as low as 0.05% and reasonable but not strong when prevalence is 1% (probability: 72.1% at best). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . 

The relationship between population infection prevalence and the probability that an is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. A further important result is that there is little -if anything -to gain in low prevalence settings from a strategy that includes a third round of testing aimed at resolving results which are discrepant between the first and second rounds of testing. Indeed, for an individual, the confidence in a positive result may be reduced by such a strategy in comparison with one that includes a second round of confirmatory testing only. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20178137 doi: medRxiv preprint

The issue of inaccurate SARS-CoV-2 infection test results has already been considered in the context of testing patients with symptoms, who have a much higher chance of being infected than asymptomatic individuals from low prevalence settings, and where the key problem is that of false negatives rather than false positives. 8 Others have discussed the problem of high numbers of falsely reassuring false positive results in the context of SARS-CoV-2 antibody testing. 9 A report from the Tony Blair Institute for Global Change, 'Changing the game on testing', which calls for population scale testing for SARS-CoV-2 infection, acknowledges that confirmatory testing for those with an initial positive result will be needed, but does not -as we do here -explore the outcomes of different testing scenarios and strategies or emphasise the critical roles of low prevalence and just slightly lower than optimal specificity in driving up the percentage of false positive results, even where confirmatory testing is conducted. 9 The strengths of our interactive tool include: the lack of any 'black box' component -all the probability calculations needed to derive the results are transparently available and the logic is carefully worked through; the flexibility for any user to examine the effects of any combination of the three parameters; the provision of results in formats that are meaningful for testing large groups or populations as well as for interpreting results for individuals; and the ability to assess different repeat testing strategies. However, although simplicity and transparency make our tool attractive, this does result in some limitations. We have assumed that all rounds of testing are independent of each other, whereas in real world situations, there may be characteristics of particular individuals (e.g., swabbing technique for selfadministered tests), sample transport systems, or laboratories (e.g. a tendency towards repeated administrative or sample handling errors) that make them inherently more prone to repeatedly inaccurate results. This could be mitigated by ensuring that confirmatory tests are not self-administered, use a different transport mechanism and are conducted in a different laboratory, fully independent of the first, as well as using a different molecular diagnostic test, but this requirement would pose significant logistical challenges. Further, since the proposed testing strategies assume that repeat testing is immediate (and so unaffected by changes in viral detection over the time course of infection), our tool is only applicable for tests with very fast turnaround of results. These are now becoming available, 10 but a detailed understanding of their performance, including sensitivity and specificity, will be required to assess their potential use in widespread testing among asymptomatic people.

In conclusion, we agree with others that population-wide testing may have an important role to play in determining local, regional and national policy for the population and in providing guidance (or even mandatory rules) for individuals. However, the crucial importance both of . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20178137 doi: medRxiv preprint extremely high test specificity and of confirmatory testing must be fully appreciated and incorporated into policy decisions if we are to avoid multiple unnecessary restrictions on individuals and on populations.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20178137 doi: medRxiv preprint

COVID-19) infection survey pilot statistical bulletins

Weekly COVID-19 testing with household quarantine and contact tracing is feasible and would probably end the epidemic

Changing the game on testing. Tony Blair Institute for Global Change

Interpreting a covid-19 test result

Test, test, test for COVID-19 antibodies: the importance of sensitivity, specificity and predictive powers

Roll-out of 2 new rapid coronavirus tests ahead of winter